The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients

Summary

Dialysis patients have a higher incidence of cardiovascular events and require more effective measures to delay the progression of heart failure. Many studies have shown that dapagliflozin has cardioprotective effect, but most studies focus on non-dialysis patients with eGFR more than 20ml/min/1.73m2. However, the data on patients with eGFR less than 20ml/min/1.73m2 or dialysis patients, especially peritoneal dialysis patients, is less. Exploring the efficacy and safety of Dapagliflozin in improving heart failure in dialysis patients is of great clinical significance.

Timeline

Start

2024-03-01

Primary completion

2024-08-31

Completion

2024-08-31

Drugs

Indications

No indication recorded.